Trials / Completed
CompletedNCT05265078
A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi
Estimating Risk of Selected Adverse Events in Patients With Von Willebrand Disease Treated With VEYVONDI® (Vonicog Alfa; Recombinant Von Willebrand Factor)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to estimate the risks of certain adverse events in adults with Von Willebrand Disease treated with VEYVONDI. No study medicines will be provided to participants in this study. Data from medical records of participants diagnosed with Von Willebrand Disease and treated with VEYVONDI will be evaluated during this study.
Conditions
Timeline
- Start date
- 2022-06-08
- Primary completion
- 2023-04-06
- Completion
- 2023-04-06
- First posted
- 2022-03-03
- Last updated
- 2023-08-31
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05265078. Inclusion in this directory is not an endorsement.